The first round of 280 million yuan financing after the completion of the spin off will accelerate product R & D

Founded in December 2010 and headquartered in Shanghai, mindI is a company specializing in cancer precision medicine In 2018, due to the rapid development of business and the need to focus on different capital markets, thinkti diagnostics business and drug R & D business completed the spin off and planned to be listed in different capital markets in the future Thingdi diagnostics continues to focus on accurate tumor diagnosis, while thingdi pharmaceuticals is committed to research and development of tumor drugs The first round of financing after the separation of mindI diagnostics will be mainly used for product R & D, including the follow-up pipeline R & D of andis closed automation ngs platform, the development of cancer early diagnosis product pipeline based on exosomes platform, and the expansion of third-party detection service product pipeline At present, thingdiagnosis has two business lines: the third-party medical inspection service and IVD (in vitro diagnosis) products It has laid out a series of product R & D pipelines, including the fields of early diagnosis, tumor associated diagnosis and tumor dynamic monitoring.